Inventus

News

In our third and final report on the 2026 Sunday Times Tech 100, we focus on the remaining crop of life sciences companies in the hardware category.

R&D

deVere and Inventus comment on the UK Autumn Budget and what it means for life sciences in the country.

News

Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.

Sales & Marketing

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.